TTOO - T2 Biosystems, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5600
-0.0500 (-1.92%)
At close: 4:00PM EDT

2.5600 0.00 (0.00%)
Pre-Market: 8:17AM EDT

Stock chart is not supported by your current browser
Previous Close2.6100
Open2.5500
Bid0.0000 x 2900
Ask0.0000 x 2200
Day's Range2.2400 - 2.6500
52 Week Range0.5200 - 7.7000
Volume1,532,100
Avg. Volume2,016,193
Market Cap111.827M
Beta (3Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-1.2840
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.22
Trade prices are not sourced from all markets
  • GlobeNewswire

    T2 Biosystems Reports Granting of Inducement Awards

    The inducement awards consist of non-qualified stock options to purchase 26,000 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $1.47, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on September 9, 2019.

  • 2 Downtrodden Small Biotechs That Are Showing Signs of Life
    TheStreet.com

    2 Downtrodden Small Biotechs That Are Showing Signs of Life

    T2 Biosystems and Replimune Group have spurted higher in the last couple weeks, with the former doubling in value on encouraging news.

  • Shares of T2 Biosystems rise on federal contract for diagnostic tests
    American City Business Journals

    Shares of T2 Biosystems rise on federal contract for diagnostic tests

    Lexington diagnostics maker T2 Biosystems is pairing up with the U.S. government to develop tests that could identify biological threats like anthrax — a deal that could alleviate some of the struggling device company’s financial concerns.

  • GlobeNewswire

    T2 Biosystems Receives Funding from BARDA to Advance Technology for Diagnosis and Treatment of Bloodstream Infections

    T2 Biosystems, Inc. (TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it has been awarded a milestone-based contract of initial value of $6 million with a potential value of up to $69 million, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services’ (HHS). The contract will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes, which are designed to improve patient outcomes and reduce the growing threat of antimicrobial resistance.

  • GlobeNewswire

    T2 Biosystems to Host Conference Call to Discuss Awarding of Multi-Million Dollar BARDA Contract

    T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today it will host a conference call and webcast to discuss the up to $69 million milestone-based contract it was awarded from the Biomedical Advanced Research and Development Authority (BARDA), which will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes. Information related to the BARDA contract is available in an 8-K filed with Securities and Exchange Commission today (available here).

  • GlobeNewswire

    T2 Biosystems Announces Restructuring of CRG Term Loan Agreement

    Reducing the minimum revenue targets for 2020 – 2022 to levels that are below the Company’s current financial forecast. For any shortfall to achieving the minimum revenue targets, the Company has the right to pay double the amount of any shortfall as an acceleration of principal payments (unchanged from existing structure). “We continue to be excited by the potential of T2 Biosystems’ direct-from-blood diagnostic technology for the prevention of sepsis and antibacterial resistance, along with future applications under development,” said Luke Düster, partner of CRG.

  • GlobeNewswire

    T2 Biosystems Awarded Breakthrough Technology Contract with Premier Inc.

    T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that Premier Inc., a healthcare improvement company, as part of their Technology Breakthroughs program, has awarded the Company a Breakthrough Technology contract. The agreement will allow Premier’s members, including a network of more than 4,000 U.S. hospitals and health systems, to receive special pricing and access to T2 Biosystems’ T2Bacteria® Panel and T2Candida® Panel – groundbreaking technology that can rapidly detect sepsis-causing pathogens in three to five hours instead of days – to foster fast, accurate therapy of bloodstream infections. “Bloodstream infections can lead to sepsis if they are not diagnosed and treated early on, which can be very serious because sepsis is associated with high mortality rates.

  • How Much is T2 Biosystems, Inc.'s (NASDAQ:TTOO) CEO Getting Paid?
    Simply Wall St.

    How Much is T2 Biosystems, Inc.'s (NASDAQ:TTOO) CEO Getting Paid?

    In 2007 John McDonough was appointed CEO of T2 Biosystems, Inc. (NASDAQ:TTOO). This report will, first, examine the...

  • GlobeNewswire

    T2 Biosystems to Present at the Janney Healthcare Conference 2019

    T2 Biosystems, Inc. (TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, chairman and chief executive officer, and John Sprague, chief financial officer, are scheduled to present at the Janney Healthcare Conference 2019. The conference is being held on September 9-10 at the Union League Club in New York City. The presentation will be webcast live and available for replay, and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com.

  • Are Options Traders Betting on a Big Move in T2 Biosystems (TTOO) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in T2 Biosystems (TTOO) Stock?

    Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

  • 4 Defensible Healthcare Stocks Gaining While the Market Falls
    TipRanks

    4 Defensible Healthcare Stocks Gaining While the Market Falls

    With the latest escalation of the U.S.-China trade war on August 23, investors are looking for defensible stocks that still represent compelling investments in a volatile market. According to research from Goldman Sachs, these investments can be found within the healthcare sector. “Funds have steadily reduced the share of market cap owned among the stocks most exposed to US-China trade conflict, such as semiconductors,” Goldman strategist Ben Snider wrote in a note to clients. He added that even with the risk of health care regulation that attracted attention from investors earlier in the year, healthcare stocks still present a strong opportunity given the economic landscape. We looked at 4 of the top August 23 gainers in this sector to find the most compelling investments. Let’s dive in. Endologix, Inc. (ELGX)Endologix develops innovative and minimally invasive technologies for aortic disorders including abdominal aortic aneurysms (AAA). With shares gaining 4% on August 23, some analysts argue this healthcare stock is just getting started. The jump comes one day after ELGX canceled its agreement with Piper Jaffray for the at-the-market sale of up to $25 million of its common stock. While this would have given the company additional capital, several recent positive developments suggest ELGX is still on track for long-term growth.On August 8, the company announced its agreement to give Boston Scientific (BSX) exclusive rights to distribute its Endologix products in China. Not to mention that same day it received Investigational Device Exemption (IDE) approval from the FDA to begin a new pivotal study evaluating the safety and effectiveness of the Nellix Chimney EndoVascular Aneurysm Sealing System (ChEVAS) for endovascular treatment of complex AAA.Based on all of the above factors, BTIG analyst Sean Lavin reiterated his Buy rating and $12 price target on August 12. The 3.5-star analyst believes share prices could soar 118% over the next twelve months.All in all, the Street is cautiously optimistic on this healthcare stock. ELGX has a ‘Moderate Buy’ analyst consensus and an $8 average price target, suggesting 51% upside. T2 Biosystems Inc. (TTOO) This healthcare stock develops and commercializes medical diagnostic products for the detection of additional species and antibiotic resistance markers of sepsis pathogens as well as tests for Lyme disease. In the last five days, shares are up 49% with shares gaining over 3% on August 23 alone.Shares got a boost shortly after T2 announced that it had entered into an exclusive agreement that will allow the company to introduce its rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, and enter into new markets in Australia, Fiji and New Zealand. These countries have approximately 1,150 hospitals that could benefit from T2’s products. It doesn’t hurt that its T2Bacteria Panel received approval for a New Technology Add-on Payment (NTAP) from the Centers for Medicare & Medicaid Services (CMS) on August 6, making it the first and only in-vitro diagnostic test to ever receive approval for NTAP.“We view this development as an unexpected victory that sort of came out of left field (as management had not indicated plans to pursue this add- on payment). While management has indicated that pricing (cost) of their panels has historically not been a meaningful barrier to driving adoption, we think that anything sold into a hospital is scrutinized from a cost and ROI perspective, even if it is clear that the technology has clinical utility for the patient,” noted Canaccord Genuity analyst Mark Massaro. As a result, the five-star analyst reiterated his Buy rating and $2.50 price target on August 6. He believes shares could soar 110% over the next twelve months. Wall Street takes a less bullish stance on TTOO. It has a ‘Hold’ analyst consensus and a $1 average price target, indicating 22% upside potential. InspireMD Inc. (NSPR)The vascular procedure technology company saw shares jump almost 2% on August 23 as well as a 32% gain in the last five days, with some analysts saying there’s no sign of a slowdown on the horizon.The upward move follows the announcement of its planned public offering of units, each consisting of one common share and one Series E warrant. Investors have expressed concern regarding a letter from the NYSE American it received on August 7, 2019. It indicated that InspireMD does not meet a certain listing standards due to the fact that the company had reported stockholders’ equity of less than $6 million as of June 30, 2019 and had net losses in its five most recent fiscal years. That being said, analyst Vernon Bernardino argues that the public offering is a move in the right direction. As a result, he reiterated his Buy rating and $5 price target. The H.C. Wainwright analyst believes shares could surge 71% in the next twelve months. NSPR boasts a ‘Moderate Buy’ analyst consensus and a $5 average price target, implying 71% upside potential. Zymeworks Inc. (ZYME)This biotech company develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. With shares up over 1% on August 23, some analysts believe now is the time to buy.Investors were impressed when ZYME posted strong Q2 earnings results on August 2. While EPS fell short of the consensus estimate by one cent, it was able to pull off a revenue beat.These results were boosted by a $7.5 million milestone payment from its partner Celgene (CELG) on July 16. The payment was triggered when CELG announced that it selected a lead oncology candidate and exercised its option for commercialization rights under their 2014 Azymetric agreement.After the news of the milestone payment broke, Deutsche Bank analyst Kostantinos Aprilakis told investors that the stock price represents a buying opportunity. This played into the analyst’s decision to initiate coverage with a Buy and set a $34 price target. He thinks shares could gain 36% in the next twelve months.In general, the Street takes a slightly more cautious stance on ZYME. It has a ‘Moderate Buy’ analyst consensus and a $29 average price target, suggesting 14% upside potential. Find analysts’ favorite stocks with the Top Analysts’ Stocks tool

  • GlobeNewswire

    T2 Biosystems Expands Access to its Innovative Rapid Diagnostic Technologies to Australia, Fiji and New Zealand

    T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into an exclusive distribution agreement that allows the Company to introduce its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, and enter into new markets in Australia, Fiji, and New Zealand. “This latest geographic expansion represents another step forward in our fight against sepsis and the negative consequences associated with it, including high mortality rates, rising hospital expenses, and growing antimicrobial resistance,” said John McDonough, chairman and chief executive officer at T2 Biosystems. “Through rapid detection of sepsis-causing pathogens in the bloodstream, the T2Bacteria Panel and T2Candida Panel have the potential to help clinicians make earlier and better informed therapy decisions that enable changes in patient outcomes.

  • GlobeNewswire

    T2Bacteria Panel is the First and Only In-Vitro Diagnostic Test to Receive Approval for a New Technology Add-on Payment by CMS

    T2 Biosystems, Inc. (TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that the United States Centers for Medicare & Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for the T2Bacteria® Panel for FY 2020. “By approving NTAP for the T2Bacteria Panel, CMS has confirmed that the T2Bacteria Panel represents a substantial clinical improvement over existing technologies,” said John McDonough, chairman and chief executive officer at T2 Biosystems.

  • Thomson Reuters StreetEvents

    Edited Transcript of TTOO earnings conference call or presentation 30-Jul-19 8:30pm GMT

    Q2 2019 T2 Biosystems Inc Earnings Call

  • Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts
    TheStreet.com

    Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

    Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.

  • Lexington diagnostics maker T2 Biosystems' stock plummets on CEO departure, low earnings
    American City Business Journals

    Lexington diagnostics maker T2 Biosystems' stock plummets on CEO departure, low earnings

    Lexington sepsis and lyme disease diagnostics maker T2 Biosystems will soon have a new CEO to lead it through its ongoing financial struggles.

  • Benzinga

    The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...

  • T2 Biosystems (TTOO) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    T2 Biosystems (TTOO) Reports Q2 Loss, Misses Revenue Estimates

    T2 Biosystems (TTOO) delivered earnings and revenue surprises of -9.38% and -10.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    T2 Biosystems Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    Announces Two Financing Agreements to Potentially Provide up to $60 Million of Additional Capital; Reducing Cash Burn by 30% by Q4 2019 Achieved $1.8 Million in Total Revenue.

  • ACCESSWIRE

    T2 Biosystems, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July, 30 2019 / T2 Biosystems, Inc. (NASDAQ: TTOO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July, 30 2019 at 4:30 PM Eastern ...

  • GlobeNewswire

    T2 Biosystems to Present at the Canaccord Genuity Growth Conference

    LEXINGTON, Mass., July 30, 2019 -- T2 Biosystems, Inc. (the “Company”) (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic.

  • GlobeNewswire

    T2 Biosystems Expands Global Access to its Innovative Rapid Diagnostic Technologies

    T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into exclusive distribution agreements with five new distribution partners in the first half of 2019. This allowed the Company to introduce its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, and enter into new markets in Estonia, Greece, Ireland, Saudi Arabia and South Africa.

  • GlobeNewswire

    T2 Biosystems Announces 2019 Second Quarter Financial and Operational Results Release and Conference Call Date

    LEXINGTON, Mass., July 24, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs.

  • Before You Buy T2 Biosystems, Inc. (NASDAQ:TTOO), Consider Its Volatility
    Simply Wall St.

    Before You Buy T2 Biosystems, Inc. (NASDAQ:TTOO), Consider Its Volatility

    Anyone researching T2 Biosystems, Inc. (NASDAQ:TTOO) might want to consider the historical volatility of the share...